2.5 mg weekly, a dose meant to help your body adjust rather than drive significant weight loss on its own
Even with severe caval/portal hypertension, BPC 157 antagonized portal and caval hypertension and aortal hypotension
Several drugs have been developed to treat T2DM such as glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase 4 inhibitors, and sodium-glucose co-transporter 2 inhibitors
Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, et al
Other studies have also found significant skeletal muscle loss, along with the desired fat loss and anti-diabetic effects of this molecule
Swiss Chems markets its products for research purposes only, and the compounds it carries are not FDA-approved for human use